B1-Ala
General Information
DCTPep ID DCTPep00517
Peptide Name B1-Ala
Sequence VKRFKKFFRKLKKAV
Sequence Length 15
UniProt ID Not available
PubChem CID Not available
Origin Cathelicidin-BF15 C-terminal amidated derivative B1
Type Synthetic peptide
Classification
ACP Tumor active peptide
Activity Information
Cell Line | Disease | Activity | Assay | Testing Time | Literature |
---|---|---|---|---|---|
K562 | Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia | IC50=8.6 µM | MTT assay | 48h | 1 |
MCF-7 | Invasive breast carcinoma of no special type | IC50=8.9 µM | MTT assay | 48h | 1 |
Hemolytic Activity Not available
Normal (non-cancerous) Cytotoxicity GES-1: IC50=87.1 µM
Target Not available
Affinity Not available
Mechanism Not available
Structure Information
PDB ID Not available
Predicted Structure DCTPep00517
(Please note that there is the predicted structure, predicted by AlphaFold)
Helicity Not available
Linear/Cyclic Linear
Disulfide/Other Bond Not available
N-terminal Modification Free
C-terminal Modification Amidation
Other Modification None
Chiral L
Physicochemical Information
Formula C94H159N27O16
Absent amino acids CDEGHIMNPQSTWY
Theoretical pI 12.05
Acidic residues 0
Basic residues 8
Polar residues 0
Molecular weight (Average) 1923.47
Molecular weight (Monoisotopic) 1922.25
Common amino acids K
Net charge 8
Instability index (II) 7.81
Aliphatic index 71.33
Grand average of hydropathicity (GRAVY) -0.667
Half Life
100 hours (mammalian reticulocytes, in vitro).
>20 hours (yeast, in vivo).
>10 hours (Escherichia coli, in vivo).
Extinction coefficients
Should not be visible by UV spectrophotometry.
Amino acid distribution
Literature Information
Literature 1
Pubmed ID 25462264
Title Design, synthesis and biological evaluation of novel peptides with anti-cancer and drug resistance-reversing activities
Doi 10.1016/j.ejmech.2014.10.072
Year 2015
Patent
Patent ID Not available
Patent Title Not available
Other Iinformation Not available
Other Published ID Not available